Serous Retinal Detachment in a Pediatric Case with Acute Lymphoblastic Leukemia as a First Sign of Leukemic Relapse

Serap Karaman1*, Gökhan Gülkilik2, Sema Vural1, Betul Aydin1, Nedim Polat3, Orhan Kızılkaya4 and Banu Arslan2
1Department of Pediatric Hematology-Oncology, Sisli Etfal Training and Research Hospital, Turkey
2Department of Ophthalmology, Istanbul Medipol University, Turkey
3Department of Pathology, Sisli Etfal Training and Research Hospital, Turkey
4Department of Radiation Oncology, Sisli Etfal Training and Research Hospital, Turkey

Abstract

A 7 year-old boy with T-cell acute lymphoblastic leukemia (T-ALL) was under treatment according to the ALL BFM 2000 protocol. Cerebrospinal fluid analysis did not reveal any blast cells at the beginning of the therapy. The patient developed bilateral visual loss at the third month of therapy. In the fundus examination there was bilateral optic disc edema, and serous retinal detachment with subretinal infiltrates. The patient with his bone marrow in remission was treated by systemic and intratechal chemotherapy combined with craniospinal and orbital radiotherapy. Subretinal fluid began to resolve and visual acuity improved, 24 hours after initiation of systemic and intratecal chemotherapy. The patient died of bone marrow relapse during preparation period for bone marrow transplantation. Acute visual loss due to serous retinal detachment may be the first sign of relapse in ALL. Detailed ophthalmic examination should be performed in patients with leukemia as early diagnosis and prompt treatment is critical.

INTRODUCTION

Ophthalmologic findings can be seen in acute lymphoblastic leukemia due to leukemic cell invasion or hematological disturbances. Although these findings are detected in the active phase of the disease, they can also be the first sign of a leukemic relapse. All parts of the eye including retina, optic nerve, and choroid can be effected [1]. While microvascular changes, intraretinal and vitreous hemorrhage and leukemic infiltrates are commonly seen, serous retinal detachment is a rare finding [2,3]. In this case, we report a 7-year-old boy with T cell ALL who was under chemotherapy and presented with acute visual loss due to serous retinal (SRD) detachment as the first sign of leukemic relapse after achieving hematological remission.

CASE REPORT

A 7 year-old boy who had been diagnosed with T-ALL was under remission with ALL BFM 2000 protocol induction treatment. During this time his ophthalmological examination was normal and he had no central nervous system involvement. At the third month of treatment, he presented with acute bilateral visual loss. He was referred to ophthalmology department for evaluation. On ophthalmological examination, visual acuities were hand motions in both eyes with normal pupil reaction without an afferent pupillary defect. Intraocular pressures (IOPs) were 18 mm Hg in the right eye and 17 mm Hg in the left eye by applanation tonometry. Anterior segment examination was normal. Dilated fundus examination showed bilateral optic disc swelling with subretinal infiltrates and microvascular changes throughout the fundus. Both veins and arteries were attenuated with venous dilatation and segmentation. Retinas were opaque and elevated with subretinal shifting fluid in both eyes (Figure 1). Diagnosis of serous retinal detachment was confirmed with magnetic resonance imaging (Figure 2). Other systemic examination findings were normal and blood tests were within normal range. There was no leukemic blasts in bone marrow aspirate. Cerebro spinal fluid (CSF) analysis revealed leukemic blast cells. Chemotherapy with intensive intrathecal therapy was initiated. His fundoscopic findings improved dramatically 2 days after the initiation of the intrathecal chemotherapy. Serous retinal detachment and optic disc edema resolved. There were focal hyperpigmentation areas consistent with RPE (retinal pigment epithelial) changes.
pigment epithelium) hypertrophy throughout the fundus. Retinal arteries and veins were attenuated (Figure 3). His visual acuity only improved to counting fingers due to the atrophic changes at the macula. When CSF analysis was repeated, no blastic activity was detected. The patient received 24 Gy orbital and craniospinal radiotherapy. During chemotherapy and radiotherapy, visual loss repeated and he had refractory seizures. The bone marrow and CSF analyses of the patient showed blast; orbital MRI showed findings consistent with retinal detachment at right bulbus oculi, with contrast activity especially at inferolateral detached retina, consistent with metastatic lesion. FLAG (Fludarabin, ARA-C) protocol was started while the bone marrow transplantation was being planned; however, the patient died at the first month of the treatment due to progression.

DISCUSSION

Serous retinal detachment occurs due to retinal pigment epithelium (RPE) damage and blood retina barrier that results in fluid accumulation underneath the neural retina. It can be seen in diseases such as malignant hypertension, toxemia of pregnancy, disseminated intravascular coagulation, diseases effecting microvascular system, and rarely malignancies [3-6].

Serous retinal detachment in leukemia is not clearly understood. Probably, leukemic infiltration of choroid or stagnation of blood flow due to hyperviscosity of blood results in dilatation, tortuosity and leakage of retinal vessels which leads to subretinal fluid accumulation. It is reported that involvement of eye was more frequent with higher leucocyte levels, especially above 50000 cells/mm³ [7]. In the present case, leucocyte count was 978000 cell/mm³ when SRD had occurred.

Serous retina detachment in leukemia most commonly occurs during the active phase of the disease [3,8,9]. In some cases ophthalmological findings may be more prominent than systemic findings and can be the first sign of a disease [8]. Serous retinal detachment as a first sign of leukemic relapse had been reported [10-15]. Most of the cases present with acute visual loss or blurry vision as in our case. In the literature, a case with an enucleated eye due to painful glaucoma refractory to treatment showed leukemic cell infiltration and detachment of the retina [11]. Ocular involvement is isolated, but mostly accompanies to central nervous system (CNS) and bone marrow involvement [7]. In our case, ocular involvement accompanied CNS involvement, but the bone marrow was in remission.

Serous retinal detachment is diagnosed clinically; USG and CT are ancillary techniques. However, USG may not show the infiltration in each case [16]. Isolation of the leukemic cells in the humour aqueous or vitreus support the diagnosis. However, it may not be easy to show the cells with needle aspiration even in cases with infiltration. In our case, SRD was diagnosed with clinical findings, fundus examination and imaging.

There is no standard treatment regimen in SRD due to leukemic infiltration. The basis of the treatment is systemic chemotherapy, and there are patients reported as chemotherapy alone being successful [8,14,17-19]. In some other centers however, the blood-retinal barrier was thought to block the chemotherapy to pass into the eye, so additional local chemotherapy or radiotherapy was used. Rootman et al [20] reported two cases with ocular leukemic relapse, and they successfully treated them with subconjunctival injections of antineoplastic agents combined by systemic and intrathecal therapy. Other cases in the literature also used radiotherapy as local treatment [3,9,11-13,21,22]. Even
there is no standard dose for radiotherapy had been described, cases who had no or less than 10 Gy ocular radiotherapy were found to have higher relapse rates, and recommended to receive minimum 30 Gy [11, 21]. In some cases, ocular findings may be refractory, even the haematologic remission is achieved, and these cases need more aggressive approaches [9]. Enucleation is also recommended if infiltrates are resistant to chemotherapy and radiotherapy [11]. Despite the multimodal treatments, the prognostic of the ocular involvement is poor [1]. In our case, the symptoms and findings regressed in 24 hours after systemic and intrathecal chemotherapy. Radiotherapy was started after induction chemotherapy, but bone marrow relapse occurred and CNS and ocular findings relapsed before the end of the treatment. The patient died at the 8th month of ALL diagnosis, and at the 2nd month of his ocular involvement with progressive disease.

As a result, in diagnosis of childhood leukemias, even rare, ocular involvement during therapy should be kept in mind, and patients with ocular findings should be examined for relapse of the disease.

REFERENCES


